We are a technology-oriented firm focused on managing all aspects of IP management, including patent litigation, due diligence in mergers and acquisitions, patent procurement and government investigations. In addition to our patent prosecution and litigation groups that procure and enforce IP assets, we also have an antitrust group that focuses on issues that are often part of a larger patent dispute, including defending our clients in class action suits. We also hired a former lead PTAB judge, Judge Brian Murphy, to handle IPR challenges to the validity of patents. In order to manage licensing and commercial aspects, we have corporate and trademark groups. When the Hatch-Waxman Act was first enacted, companies often had to hire separate law firms for FDA, antitrust, transactions, and litigation, making the entire process cumbersome. Haug Partners was the first (and perhaps still only) IP firm to offer a one-stop shop that draws from all of these areas to streamline the process for our clients.

Nick: Unlike other players in the industry, Haug Partners takes an immediate multidisciplinary approach to address the challenges faced by our innovator clients. From day one, every case that comes our way is staffed with individuals who can anticipate and address all possible contingencies. Another differentiating factor is our knowledge and experience with specific venues. There are certain courts in Delaware, New Jersey, California, and Texas where many of our cases proceed, as patent litigation tends to gravitate towards these courts for various reasons. Our intimate knowledge of the judges in these districts give us a significant edge over other firms. Another distinguishing factor is that many of our partners hold leadership positions on the important IP-related bar associations that allow us to stay up to speed on judicial trends and legislative developments.

Can you shed some light on the client onboarding process at Haug Partners?

Ed: We undertake a practical, dynamic approach to onboarding clients that allows us to analyze their requirements and devise comprehensive solutions. Our pharmaceutical clients run from large companies to startups, including Takeda, Sanofi, Supernus, Celgene, Biogen, and others. We also have strong relationships with some of the world’s largest automobile manufacturers and technology companies.

Can you share an example of how you helped a client address a significant problem?

Ed: An example that comes to mind is a multi-billion dollar pharmaceutical case where we represented Shire Pharmaceuticals. Shire was facing the loss of its flagship product, Adderall XR, which is an important treatment for ADHD. Haug Partners was initially hired as co-counsel, but seeing our expertise in this area, Shire made the decision to transition us to lead counsel. Our team was able to protect Shire’s market through multiple court victories and settlements over several years, laying the groundwork for its growth into one of the world’s most successful specialty pharma companies.

What does the future hold for Haug Partners?

Nick: In addition to our focus on the Pharmaceutical Industry, we continue to expand our services, capabilities, and client base in other markets, such as automobile, microchip, drones, biotech, cryptocurrency, and others.

Ed: Starting with about 10 attorneys in 1997, Haug Partners now has 75 attorneys spread across its offices in Boston, New York, and Washington, DC. We are today the largest IP focused firm in New York City and are continuing our efforts to expand to Florida in order to eventually cover the entire east coast, from Boston to Miami.